In order to investigate the evolution of the NRAS/BRAF double mutated cancer cells within a patient, we analyzed tumor DNA for the presence of double mutations in all available histological and frozen material from patients 4, 5, 6, 7 and 8 before and after BRAF inhibitor treatment (Table 1). The gene discussed is BRAF; the disease is cancer.